Thursday, February 21, 2019 3:13:04 PM
Alan,
Thanks for your inquiry. At this time, we are struggling with keeping the current business plan funded. We have not been able to attract sufficient venture capital to cover current G&A expenses let alone furthering clinical trials and product development. We have done extensive broker roadshows via Renmark for two years and have used other methods to identify sources of capital and to find investors willing to back the company. In our last fiscal year this amounted to dozens of presentations in cities all over Canada and the US that were attended by over 300 brokers. Over the last six months, insiders have loaned the company over $300,000 until proper financing could be put into place. The lack of outside investor interest is forcing us to look at any all options from selling the technology to joint ventures. If you have any ideas for us to consider please do send them along.
Eric
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM